Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T.
Shimose S, et al. Among authors: moriyama e.
Hepatol Res. 2023 Feb;53(2):116-126. doi: 10.1111/hepr.13852. Epub 2022 Nov 16.
Hepatol Res. 2023.
PMID: 36316794